A RANDOMIZED STUDY TO DETERMINE WHETHER ROUTINE INTRAVENOUS MAGNESIUMSUPPLEMENTS ARE NECESSARY IN PATIENTS RECEIVING CISPLATIN CHEMOTHERAPY WITH CONTINUOUS-INFUSION 5-FLUOROURACIL
Trj. Evans et al., A RANDOMIZED STUDY TO DETERMINE WHETHER ROUTINE INTRAVENOUS MAGNESIUMSUPPLEMENTS ARE NECESSARY IN PATIENTS RECEIVING CISPLATIN CHEMOTHERAPY WITH CONTINUOUS-INFUSION 5-FLUOROURACIL, European journal of cancer, 31A(2), 1995, pp. 174-178
Cisplatin is an effective antineoplastic agent, but can cause renal tu
bular damage leading to urinary magnesium wasting and hypomagnesaemia.
Cisplatin and 5-fluorouracil, when used in combination, have synergis
tic antitumour activity in upper gastrointestinal malignancies, but it
is unclear whether they have additive effects on renal magnesium loss
. To determine the optimal regimen for magnesium supplementation in th
ese patients, we have conducted a randomised trial of routine intraven
ous magnesium supplements compared with magnesium given on an 'as requ
ired' basis. 32 patients were randomised to receive magnesium intraven
ously in prehydration and posthydration fluids with cisplatin chemothe
rapy, or to receive magnesium only when the serum level was low. 5-flu
orouracil was given as a continuous infusion. Serum magnesium was meas
ured on admission for each cycle of chemotherapy and an interim measur
ement performed between each cycle. 28 patients were evaluable. All pa
tients randomised to receive magnesium on an 'as required' basis had a
t least one episode of hypomagnesaemia. On subsequent admissions for c
hemotherapy (cycles 2 and 3), the mean serum magnesium level was signi
ficantly lower in these patients compared with patients who received m
agnesium routinely (P < 0.05). After omission of magnesium from the fi
rst cycle of cisplatin, magnesium supplements were necessary in 50% of
subsequent cycles, usually by the second or third cycle. Moreover, th
ere were several instances of symptomatic hypomagnesaemia requiring fu
rther intravenous supplements in mid-cycle. Patients treated with a co
mbination of cisplatin and 5-fluorouracil should be given intravenous
magnesium supplements with each cycle of cisplatin chemotherapy. Never
theless, episodes of hypomagnesaemia still occur, and additional intra
venous supplements may be required, highlighting the importance of mea
suring this electrolyte.